Mesoblast Limited

NASDAQ:MESO

Biotechnology

Healthcare
$11.64 +1.86%

+$0.26 today

Market cap
$1.51B
Beta
0.79
P/E (TTM)
-23.6
EPS (TTM)
-$0.06
52W Low $9.88High $21.50

Volume 0.13M

Average 0.21M

MESO Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Mesoblast LimitedNASDAQ: MESO

Net Margin · Q4 FY2026 · quarter ended Jun 2026

Net margin widens to -25.2%

Net margin was -25.2% in Q4 FY2026, up 360.9 pp from a year earlier. On a trailing-twelve-month basis it was -47.8%, up 546.1 pp year over year. Over 3 fiscal years it widened by 1043.9 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.
  • FY2026 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 3 analysts of -13.7% for the fiscal year ending Jun 2027, up from -47.8% in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-25.2%+0.0 pp QoQ
Last fiscal yearJun 2026
-47.8%+546.1 pp YoY
LTMJun 2026
-47.8%+546.1 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+360.9 pp+44.5 pp-316.4 pp
1 year+546.1 pp+34.1 pp-512.0 pp
3 years+1043.9 pp+69.5 pp-974.4 pp
5 years+98.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2026
-47.8%
Year-over-year change
+546.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How MESO compares with its peers on the latest reported figures

  • MESO's LTM Jun 2026 net margin of -47.8% is the 2nd highest of the 5 companies compared; the peer median is -389.9%.
  • Its year-over-year change of +546.1 pp is the highest of 5, against a peer median of -251.8 pp.
  • Over three fiscal years its change of +1043.9 pp compares with a peer median of -341.2 pp.
MESO Competitors Peer median
Net Margin for MESO and competitors
Company Period LTM level YoY 3-year change
LEGNLegend Biotech CorporationLTM Sep 2026-0.0% +26.4 pp+352.6 pp
MESOMesoblast LimitedLTM Jun 2026-47.8% +546.1 pp+1043.9 pp
CELUCelularity Inc.LTM Dec 2025-345.4% -238.7 pp-424.7 pp
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026-434.4% -264.9 pp-257.8 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-2056.8% -737.9 pp-1758.5 pp
CAPRCapricor Therapeutics, Inc.FY2025— ——
Peer median (excluding MESO) -389.9%-251.8 pp-341.2 pp

Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue10.21M7.5M5.9M17.2M120.79M
Cost of Revenue63.57M54.92M41.07M5.13M19.21M
Gross Profit(53.36M)(47.42M)(35.17M)12.07M101.58M
Gross Margin-522.6%-632.2%-595.9%70.2%84.1%
Research & Development32.82M27.19M25.35M34.81M97.94M
Selling, General & Admin57.97M53.11M23.63M39.31M55.13M
Operating Expenses90.79M76.79M48.98M74.51M153.08M
Depreciation & Amortization4.38M4.11M1.9M6.4M8.62M
EBITDA(76.57M)(58.55M)(56.08M)(73.66M)(42.88M)
EBITDA Margin-749.9%-780.6%-950.1%-428.3%-35.5%
Operating Income(80.57M)(69.29M)(84.15M)(62.44M)(51.5M)
Operating Margin-789.1%-923.7%-1425.7%-363.1%-42.6%
Interest Income0831K1.82M3.55M3.93M
Interest Expense17.29M19.44M20.66M22.93M23.95M
Other Income / Expenses(10.48M)(12.81M)(4M)(39.37M)(5.64M)
Income Before Tax(91.59M)(82.1M)(88.15M)(101.81M)(57.14M)
Pre-Tax Margin-896.9%-1094.5%-1493.5%-592.0%-47.3%
Income Tax Expense(239K)(212K)(191K)330K615.74K
Net Income(91.35M)(81.89M)(87.96M)(102.14M)(57.76M)
Net Margin-894.6%-1091.7%-1490.3%-593.9%-47.8%
EPS (Basic)(1.30)(0.98)(0.89)(0.84)(0.45)
EPS (Diluted)(1.30)(0.98)(0.89)(0.84)(0.45)
Weighted Avg Shares68.27M83.77M98.67M120.78M129.49M
Weighted Avg Shares (Diluted)68.29M83.93M98.67M120.78M129.49M

Mesoblast Limited

NASDAQ:MESO

Intrinsic Alpha fair value

Locked

Current Price

$11.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.